Furthermore, AESIS-1 suppressed STAT3 activation in splenocytes isolated from mice with severe CIA and decreased the number of polarized Th17 cells, implying that it could be an effective therapeutic agent for treating various autoimmune diseases, including RA, characterized as STAT3-hyperactivated or Th17-cell-dominant. This evidence concerns the gene STAT3 and rheumatoid arthritis.